Dr. Gary Kurtzman is Managing Director, Healthcare at Safeguard Scientifics (NYSE:SFE). At Safeguard, Gary partners with emerging- and growth-stage companies in healthcare IT, diagnostics and devices. With more than 25 years of experience as an entrepreneur, board member, financier and operator, Gary leverages his medical expertise to empower businesses to enhance their products, grow their services and identify strategic partnership opportunities. Gary has realized value for companies through a series of successful IPOs, M&A and turnaround transactions -- most recently Shire’s acquisition of Safeguard’s partner company Advanced BioHealing for $750 million, in cash; and Eli Lilly’s acquisition of Safeguard’s partner company Avid Radiopharmaceuticals for $300 million, up front, with an additional $500 million payout dependent upon the achievement of future regulatory and commercial milestones.


Gary’s previous experiences include leadership roles at BioAdvance, Pluvita Corporation, Genovo, Avigen, and Gilead Sciences, at the time a pre-IPO biotech company. Presently, Gary is a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences. In addition, he is also a member of the board at Safeguard’s partner companies Alverix, Crescendo Bioscience, Good Start Genetics, Medivo, and PixelOptics. A board-certified internist from Barnes Hospital in St. Louis, MO, with a hematology sub-specialty from Stanford, Gary has authored more than 40 research articles, book chapters, and reviews, and is credited as inventor on 12 issued United States patents. Gary received his Bachelor of Science from Stanford University and Doctorate from Washington University.